Sugi Predict

Sugi Predict / Compounds / SCHEMBL336060

SCHEMBL336060

SCHEMBL336060

O=C(O)c1ccc(F)c(C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.52
▸ LMNA P02545 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ TSHR P16473 4/20 0.48
▸ TP53 P04637 1/20 0.48
▸ GAA P10253 3/20 0.46
▸ CES2 O00748 2/20 0.46
▸ CES1 P23141 2/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ CA4 P22748 1/20 0.46
▸ CA6 P23280 1/20 0.46
▸ PTGS2 P35354 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358318 0.89 TDP1 (0.55) KDM4ECES2CES1POLBL3MBTL1
SCHEMBL27952405 0.85 LMNA (0.46) KDM4ELMNARAB9AMAPK1HTT
SCHEMBL17478757 0.85 AKR1C3 (0.53) —
SCHEMBL8639693 0.85 RAB9A (0.50) KDM4ELMNARAB9AMAPK1HTT
SCHEMBL2581290 0.85 PARP1 (0.47) KDM4ETSHRCES2CES1POLB
SCHEMBL730390 0.84 CES2 (0.41) KDM4ELMNARAB9AMAPK1HTT
SCHEMBL8558758 0.82 PLA2G2D (0.55) KDM4ELMNARAB9AMAPK1HTT
SCHEMBL14421297 0.82 POLB (0.53) KDM4ELMNARAB9AMAPK1HTT
SCHEMBL17262460 0.82 SORT1 (0.45) KDM4ELMNARAB9AMAPK1HTT
SCHEMBL460421 0.82 LMNA (0.55) KDM4ELMNARAB9AMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118183707-A Fluorocarbon material and preparation method and application thereof 重庆大学锂电及新材料遂宁研究院 2024-06-14 — — CN claimed
CN-118183707-A Fluorocarbon material and preparation method and application thereof 重庆大学锂电及新材料遂宁研究院 2024-06-14 — — CN disclosed
WO-2024049929-A2 PANNEXIN-1 MODULATORS AND METHODS OF TREATING DISORDERS IN WHICH PANNEXIN-1 IS IMPLICATED PANNEX THERAPEUTICS INC. (US) 2024-03-07 — — WO disclosed
CN-112778518-B Amide-bridged organic polymer hole transport material and synthesis method and application thereof 天津理工大学 2022-07-22 — — CN disclosed
CN-112778518-A Amide-bridged organic polymer hole transport material and synthesis method and application thereof 天津理工大学 2021-05-11 — — CN disclosed
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 — — US disclosed
EP-3286174-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2018-02-28 — — EP disclosed
US-9869027-B2 Cleaning composition and method of manufacturing metal wiring using the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-01-16 — — US disclosed
US-20170255100-A1 DRY FILM STRUCTURE FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. 2017-09-07 — — US disclosed
WO-2016172425-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE (NO.5) LIMITED (GB) 2016-10-27 — — WO disclosed
EP-1646608-A1 TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JE IL Pharmaceutical Co., Ltd. (KR) 2006-04-19 — — EP disclosed
WO-2006030873-A1 POLYAMIDE, FILM, AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2006-03-23 — — WO disclosed
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 — — US disclosed
EP-1602641-A1 BIS(3-AMINO-4-HYDROXYPHENYL)ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF IDEMITSU KOSAN COMPANY LIMITED (JP) 2005-12-07 — — EP disclosed
WO-2005097773-A1 1,1’-(1,2-ETHYNEDIYL)BIS-BENZENE DERIVATIVES AS PTP 1-B INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-10-20 — — WO disclosed
WO-2004113281-A1 TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JE IL PHARMACEUTICAL CO., LTD. (KR) 2004-12-29 — — WO disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 — — US disclosed
EP-1339702-A1 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-09-03 — — EP disclosed
US-20020076535-A1 Thermally curable fluorinated o-aminophenol and aromatic dicarbolxylic acid polymer or oligomer for dielectric materials with excellent thermal, dielectric and mechanical properties and solvent resistance FUJITSU LIMITED (JP) 2002-06-20 — — US disclosed
WO-2001068619-A1 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEX INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 KDM4E 1568/4885LMNA 2398/4885RAB9A 3021/4885
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E KDM4E 2426/4885LMNA 3382/4885RAB9A 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.